Inovelon Opinion Heralds Opportunities For Eisai

Innovative Japanese drugmaker Eisai has received a positive opinion on its anti-epileptic Inovelon (rufinamide) from the European Committee for Medicinal Products (CHMP). The drug already has orphan drug status in the EU and the US for Lennox-Gastaut syndrome, a severe form of childhood onset epilepsy. A wider indication for the product, which was developed as a wide-spectrum anticonvulsant, could secure Eisai additional revenues in this expanding disease

To read the full article, please choose one of the following options: